We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
CBD oil
An SI Board Since August 2018
Posts SubjectMarks Bans Symbol
140 8 0 CVSI
Emcee:  alwaysbmiki Type:  Moderated
vent: CV Sciences Third Quarter 2018 Financial Results Call
Date: Wednesday, November 7, 2018
Time: 1:15pm PT/4:15pm ET
Telephone access (U.S. and Canada): 877-407-8293
Telephone access (International): 201-689-8349
Live webcast: CV Sciences Investor Section

Cv Sciences Inc0.89 (27.7259) at 4.1

By: CV Sciences, Inc. via GlobeNewswire News Releases
August 30, 2018 at 08:45 AM EDT

CV Sciences, Inc. provides corporate update to shareholders

LAS VEGAS, Aug. 30, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. ( OTCQB:CVSI) (the “Company”, “CV Sciences”, “our” or “we”) would like to assure our shareholders that we are keenly aware of recent market activity and certain disinformation disseminated by persons holding short positions in our stock.

“As many of our shareholders are aware, our Company has been victimized by campaigns run by short sellers in order to depress our stock price, so they could make financial windfalls,” stated Joseph Dowling, Chief Executive Officer of CV Sciences. “We are also aware that at least one such group has boasted on social media platforms about its financial returns since their release of misleading information regarding the Company’s patent prosecution and drug development efforts.”

Mr. Dowling continued, “While we don’t normally comment on our stock price or performance, it is important to stress that nothing has fundamentally changed in our business. We continue to deliver solid financial results, and we remain very confident in our prospects.”

Over the last year, the Company has achieved numerous milestones and market-leading fundamentals. Some notable items include:

  • Record-breaking Q2 2018 financial results including revenues of $12.3 million, net income of $3.2 million and adjusted EBITDA of $3.8 million.
  • Record-breaking first half 2018 financial results including revenues of $20.4 million, net income of $3.8 million and adjusted EBITDA of $5.6 million.
  • Recent repayment of remaining debt obligations resulting in a much stronger, debt-free balance sheet.
  • Market-leading retail distribution of our PlusCBD Oil™ brand to 1,968 stores as of June 30, 2018.
  • Accelerated investment to increase our operating scale to take advantage of a fast-growing market, expected to reach $1.6 billion by 2021.
  • Strong trade leadership role to advocate passage of the 2018 Farm Bill to further solidify industry legal framework.
  • Actively prosecuting our U.S. Patent Application No. 15/426,617 (the ‘617 Application) with plans to file and prosecute several more applications related to the ‘617 Application. Also, we have commenced foreign patent prosecution for the ‘617 Application based on our global strategy to commercialize our drug candidate CVSI-007.
  • Ranking among the leading financial performers in our sector especially when measured against comparable public companies including Tilray Inc., Cronos Group Inc. and Canopy Growth Corporation.
  • Submitting up-listing application with NASDAQ Capital Market, which would allow the Company to broaden our investor pool and provide greater access to capital markets.
  • “We sympathize with our shareholders for having to endure this short selling activity, and the manipulations and misinformation that come along with it,” stated Mr. Dowling. “We will continue to do everything in our control to bring this activity to a halt. In the months ahead, we look forward to reporting our operating results in this fast-growing industry and providing updates on our drug development efforts.”

    About CV Sciences, Inc.

    CV Sciences, Inc. ( OTCQB:CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from or by visiting


    This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.


    Robert Haag
    Managing Director
    IRTH Communications

    Related Stocks:
    Cv Sciences Inc

    Data & News supplied by
    Stock quotes supplied by Six Financial & Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.

    Copyright © 1995-2016 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.
    Previous 25 | Next 25 | View Recent | Post Message
    Go to reply# or date (mm/dd/yy):
    ReplyMessage PreviewFromRecsPosted
    139Well still holding few shares but should I ????alwaysbmiki-5/16/2020
    138AUDIO CV Sciences, Inc Reports Third Quarter 2019 youtube.comalwaysbmiki-11/6/2019
    136This is huge. otcmarkets.comalwaysbmiki-8/22/2019
    135Press Releases CV Sciences, Inc. Reports Second Quarter 2019 Financial Results alwaysbmiki-8/6/2019
    134CV Sciences, Inc. to Announce Second Quarter 2019 Results on August 6, 2019 ir.alwaysbmiki-7/27/2019
    133Cant stop that CBD. Curaleaf undervalued now and a buy IMHOalwaysbmiki-7/16/2019
    131 CV Sciences, Inc. Announces Commitment to More Than 500 Acres of U.S. Hemp Pralwaysbmiki-7/10/2019
    129Take that FDA!alwaysbmiki16/17/2019
    127Thank you Ron, big news!!!alwaysbmiki-6/12/2019
    126Kroger to sell CBD oil in 17 states-- 945 Stores benzinga.comRon16/11/2019
    125Cannabis stocks fall after FDA hearing on CBD finds conflicting views of substanRon16/3/2019
    124CBD-infused beverages are on the rise, but face major issue: The cannabis compoualwaysbmiki-5/22/2019
    123A Call For Science In A Congested CBD World ibtimes.comSultan15/20/2019
    122So true... Nice read , thank you ~!alwaysbmiki-5/19/2019
    121An entire industry is being built around CBD, but we really don’t know that muchSultan-5/19/2019
    120Thank you sir. I am still holding shares and glad I am after this report.alwaysbmiki-5/14/2019
    119CV Sciences’ PlusCBD Oil™ Used in First Study Examining Clinical Benefit of CBD Sultan15/14/2019
    118Edited Transcript of CVSI earnings conference call or presentation 8-May-19 finSultan15/14/2019
    1171st Quarter 2019 Audio conf call youtube.comalwaysbmiki-5/8/2019
    116CV Sciences, Inc. to Present at Upcoming Investor Conferences LAS VEGAS, May 07Sultan15/7/2019
    Previous 25 | Next 25 | View Recent | Post Message
    Go to reply# or date (mm/dd/yy):